Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

  1. de Andrés-Nogales, F.
  2. Oyagüez, I.
  3. Álvarez-Sala, L.A.
  4. García-Bragado, F.
  5. Navarro, A.
  6. González, P.
  7. Elías, I.
  8. Soto, J.
Aldizkaria:
Pharmacoeconomics - Spanish Research Articles

ISSN: 1989-5453,  1695-405X

Argitalpen urtea: 2017

Alea: 14

Zenbakia: 1

Orrialdeak: 7-18

Mota: Artikulua

DOI: 10.1007/S40277-016-0064-8 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus